Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Stivarga

- PMLiVE

Bayer launches ‘Anything but Normal’ campaign highlighting women’s health issues

Over 1.5 billion women worldwide – almost one in two women – experience women’s health issues

- PMLiVE

AstraZeneca’s Imfinzi/Imjudo regimen recommended by NICE to treat liver cancer

Approximately 6,600 people are diagnosed with liver cancer every year in the UK

- PMLiVE

Bayer’s Kerendia granted FDA approval for new heart failure indication

Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

- PMLiVE

BMS receives FDA approval for immunotherapy combination in liver cancer

Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

- PMLiVE

Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

- PMLiVE

BMS granted EC approval for immunotherapy combination in liver cancer

More than 866,100 cases of the disease were diagnosed globally in 2022

- PMLiVE

FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

The progressive neurodegenerative disease affects more than ten million people worldwide

- PMLiVE

BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

- PMLiVE

Bayer UK launches digital educational hub to improve menopause support

An estimated 13 million women in the UK are currently perimenopausal or menopausal

- PMLiVE

Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

- PMLiVE

AstraZeneca shares ‘unprecedented’ survival results for Imfinzi/Imjudo regimen in liver cancer

Almost 900,000 new cases of liver cancer are diagnosed globally every year

- PMLiVE

Bayer presents positive results for Kerendia in late-stage heart failure study

Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links